TABLE 1.
Ligands | DOPR/βarr2 |
MOPR/βarr2 |
||||
---|---|---|---|---|---|---|
Emax (±S.E.) | Log EC50 (±S.E.) | n | Emax (±S.E.) | Log EC50 (±S.E.) | n | |
Bremazocine | 0.01 (0.02) | NM | 3 | <0.01 | NM | 2 |
Buprenorphine | 0.013 (0.06) | NM | 3 | 0.023 (0.01) | −7.2 (0.14) | 3 |
DAGO | 0.8 (0.1)a | −3.2 (0.3)a | 3 | 0.89 (0.06) | −6.7 (0.08) | 13 |
[d-Ala2]-deltorphin | 1.07 (0.02) | −7.5 (0.32) | 3 | 0.95 (0.05)a | −4.1 (0.2)a | 3 |
Dermorphin | 0.97 (0.02) | −4.2 (0.10) | 3 | 0.93 (0.02) | −7.5 (0.06) | 6 |
Diprenorphine | 0.14 (0.09) | −7.9 (0.19) | 5 | 0.012 (0.002) | NM | 3 |
[d-Pen2,d-Pen5]-enk | 0.97 (0.04) | −7.6 (0.27) | 3 | 0.71a | −3.1 (0.6)a | 3 |
Ethylketocyclazocine | 0.12 (0.03) | −6.0 (0.17) | 3 | 0.05 (0.02) | −7.8 (0.14) | 3 |
Endomorphine 2 | NM | >−3 | 2 | 0.94 (0.04) | −7.3 (0.33) | 8 |
Etorphine | 0.74 (0.07) | −6.8 (0.25) | 4 | 0.95 (0.02) | −8.5 (0.11) | 5 |
Fentanyl | 0.01 (0.06) | NM | 3 | 0.77 (0.10) | −6.6 (0.18) | 3 |
Lofentanyl | 0.78 (0.02) | −7.0 (0.13) | 3 | 1.06 (0.04) | −8.4 (0.08) | 7 |
Meperidine | 0.013 | NM | 2 | 0.41 (0.2)a | −3.2 (0.31)a | 3 |
Met-enkephalins | 1.05 | −7.1 | 1 | 1.08 | −6.4 | 1 |
Morphiceptin | <0.01 | NM | 2 | 0.68 (0.07) | −5.0 (0.21) | 5 |
Morphine | 0.08 (0.04) | NM | 3 | 0.24 (0.02) | −6.4 (0.08) | 6 |
Oxymorphone | 0.09 (0.03) | −5.3 (0.46) | 3 | 0.20 (0.02) | −6.8 (0.09) | 8 |
SNC-121 | 0.96 (0.09) | −5.3 (0.29) | 6 | NM | >−3 | 2 |
UFP-512 | 0.27 (0.02) | −9.0 (0.15) | 3 | <0.01 | NM | 2 |
[d-Ala2,d-Leu5]-enk | 1 | −7.6 (0.1) | 17 | 1 | −6.5 (0.08) | 21 |
a Values were extrapolated from data fitting but were not well defined experimentally because the curve did not reach a full upper asymptote.